ALDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALDX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is unwilling to wait for a better entry. The stock has some short-term stabilization, but the broader picture is still driven by FDA setbacks, weak analyst sentiment, and extremely speculative options activity. I would not buy now; I would hold off until there is clearer fundamental progress or a stronger technical breakout.
The stock is trading near 1.73, just above the prior close of 1.71, with a modest gain and no strong trend confirmation. MACD is slightly positive but contracting, RSI_6 is neutral at 50.6, and moving averages are converging, which points to a sideways and indecisive trend rather than a confirmed uptrend. Key levels show pivot resistance at 1.754 with resistance at 1.901 and 1.992, while support sits at 1.607 and 1.516. In short, the chart does not show a strong buy setup right now. The stock trend model also suggests only modest near-term upside, with a 50% chance of -1.45% next day, 0.08% next week, and 2.85% next month.
Aldeyra recently appointed Darlene Deptula-Hicks to its board, which adds experienced biotechnology leadership and could improve strategic execution. The stock also has a small recent price uptick and a neutral-to-slightly positive MACD reading, suggesting some short-term stabilization. If the company makes meaningful progress on reproxalap or regains regulatory confidence, sentiment could improve quickly from current depressed levels.
The most important negative catalyst is the FDA complete response letter tied to reproxalap for dry eye disease, which led to a major analyst downgrade and sharply reduced the perceived probability of success. Analyst price target was cut from $10 to $2, which is a severe reset in expectations. The business currently lacks a strong financial snapshot in the provided data, there is no valuation support, and both hedge funds and insiders are neutral with no meaningful buying trend. Options activity also reflects very high uncertainty and heavy put volume. There is no supportive congress trading data or influential figure activity to offset this.
No usable latest-quarter financial snapshot was provided, so there is no confirmed revenue or earnings growth trend to support a long-term buy case. The absence of current quarterly financial detail makes it difficult to justify the stock for a beginner investor seeking clearer fundamentals.
Sentiment has turned bearish. On 2026-03-18, H.C. Wainwright downgraded Aldeyra to Neutral from Buy and slashed the price target from $10 to $2 after the FDA complete response letter. This is a major negative shift in Wall Street expectations. The pros view now appears cautious to bearish: some residual upside exists if the pipeline recovers, but the cons dominate because regulatory risk and probability-of-success reassessment have materially weakened the investment case.
